MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Confe...(loaded staccato bursts or pulses are k...)

Date:2/5/2008

loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

'/>"/>

SOURCE MiddleBrook Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Anthera Pharmaceuticals Forms Scientific Advisory Board
5. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
6. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
10. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Access Pharmaceuticals Announces $2.7 Million New Equity